These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

758 related articles for article (PubMed ID: 32350047)

  • 41. The Promise and Peril of Antibody Testing for COVID-19.
    Abbasi J
    JAMA; 2020 May; 323(19):1881-1883. PubMed ID: 32301958
    [No Abstract]   [Full Text] [Related]  

  • 42. High Incidence of False-Positive Results in Patients with Acute Infections Other than COVID-19 by the Liaison SARS-CoV-2 Commercial Chemiluminescent Microparticle Immunoassay for Detection of IgG Anti-SARS-CoV-2 Antibodies.
    Boukli N; Le Mene M; Schnuriger A; Cuervo NS; Laroche C; Morand-Joubert L; Gozlan J
    J Clin Microbiol; 2020 Oct; 58(11):. PubMed ID: 32848041
    [No Abstract]   [Full Text] [Related]  

  • 43. Comparison of serologic and molecular SARS-CoV 2 results in a large cohort in Southern Tuscany demonstrates a role for serologic testing to increase diagnostic sensitivity.
    Pancrazzi A; Magliocca P; Lorubbio M; Vaggelli G; Galano A; Mafucci M; Duranti D; Cortesi M; Mazzeschi E; Fabbroni S; Viti G; Tartaglia Polcini A; Tripodo E; Sanchini P; Gervino S; Tacconi D; Dei S; Mazzierli M; D'Urso A; Ognibene A
    Clin Biochem; 2020 Oct; 84():87-92. PubMed ID: 32702365
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of an Electrochemiluminescent SARS-CoV-2 Antibody Assay.
    Lau CS; Hoo SP; Yew SF; Ong SK; Lum LT; Heng PY; Tan JG; Wong MS; Aw TC
    J Appl Lab Med; 2020 Nov; 5(6):1313-1323. PubMed ID: 32717060
    [TBL] [Abstract][Full Text] [Related]  

  • 45. How ADA methodology informs SARS-CoV-2 assay development.
    Becker C
    Bioanalysis; 2020 Sep; 12(18):1275-1277. PubMed ID: 32915061
    [No Abstract]   [Full Text] [Related]  

  • 46. Clinical Performance of the Roche SARS-CoV-2 Serologic Assay.
    Tang MS; Hock KG; Logsdon NM; Hayes JE; Gronowski AM; Anderson NW; Farnsworth CW
    Clin Chem; 2020 Aug; 66(8):1107-1109. PubMed ID: 32484860
    [No Abstract]   [Full Text] [Related]  

  • 47. Evaluation of an ELISA for SARS-CoV-2 antibody testing: clinical performances and correlation with plaque reduction neutralization titer.
    Padoan A; Bonfante F; Sciacovelli L; Cosma C; Basso D; Plebani M
    Clin Chem Lab Med; 2020 Oct; 58(11):e247-e249. PubMed ID: 32772001
    [No Abstract]   [Full Text] [Related]  

  • 48. Waiting for Certainty on Covid-19 Antibody Tests - At What Cost?
    Weinstein MC; Freedberg KA; Hyle EP; Paltiel AD
    N Engl J Med; 2020 Aug; 383(6):e37. PubMed ID: 32501664
    [No Abstract]   [Full Text] [Related]  

  • 49. Serology assays to manage COVID-19.
    Krammer F; Simon V
    Science; 2020 Jun; 368(6495):1060-1061. PubMed ID: 32414781
    [No Abstract]   [Full Text] [Related]  

  • 50. Diagnostic performance of COVID-19 serology assays.
    Zainol Rashid Z; Othman SN; Abdul Samat MN; Ali UK; Wong KK
    Malays J Pathol; 2020 Apr; 42(1):13-21. PubMed ID: 32342927
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection.
    Hachim A; Kavian N; Cohen CA; Chin AWH; Chu DKW; Mok CKP; Tsang OTY; Yeung YC; Perera RAPM; Poon LLM; Peiris JSM; Valkenburg SA
    Nat Immunol; 2020 Oct; 21(10):1293-1301. PubMed ID: 32807944
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Testing for SARS-CoV-2 antibodies.
    Watson J; Richter A; Deeks J
    BMJ; 2020 Sep; 370():m3325. PubMed ID: 32900692
    [No Abstract]   [Full Text] [Related]  

  • 53. Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients.
    Yongchen Z; Shen H; Wang X; Shi X; Li Y; Yan J; Chen Y; Gu B
    Emerg Microbes Infect; 2020 Dec; 9(1):833-836. PubMed ID: 32306864
    [TBL] [Abstract][Full Text] [Related]  

  • 54. SARS-CoV-2 serology: Test, test, test, but interpret with caution!
    Bermingham WH; Wilding T; Beck S; Huissoon A
    Clin Med (Lond); 2020 Jul; 20(4):365-368. PubMed ID: 32487681
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Patients who have recovered from covid-19: issuing certificates and offering voluntary registration.
    Bhopal R
    BMJ; 2020 Jul; 370():m2590. PubMed ID: 32611552
    [No Abstract]   [Full Text] [Related]  

  • 56. Rapid Gel Card Agglutination Assays for Serological Analysis Following SARS-CoV-2 Infection in Humans.
    Alves D; Curvello R; Henderson E; Kesarwani V; Walker JA; Leguizamon SC; McLiesh H; Raghuwanshi VS; Samadian H; Wood EM; McQuilten ZK; Graham M; Wieringa M; Korman TM; Scott TF; Banaszak Holl MM; Garnier G; Corrie SR
    ACS Sens; 2020 Aug; 5(8):2596-2603. PubMed ID: 32672954
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Rapid point-of-care serology testing for sars-cov-2].
    Stackelberg O; Esmaeilzadeh M; Olsen B; Lundkvist Å
    Lakartidningen; 2020 May; 117():. PubMed ID: 32463475
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characteristics and assessment of the usefulness of serological tests in the diagnostic of infections caused by coronavirus SARS-CoV-2 on the basis of available manufacturer's data and literature review.
    Rastawicki W; Rokosz-Chudziak N
    Przegl Epidemiol; 2020; 74(1):49-68. PubMed ID: 32500987
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of Three Commercial Automated Assays for the Detection of Anti-SARS-CoV-2 Antibodies.
    Harb R; Remaley AT; Sacks DB
    Clin Chem; 2020 Oct; 66(10):1351-1353. PubMed ID: 32761081
    [No Abstract]   [Full Text] [Related]  

  • 60. Preliminary evaluation of Roche Cobas Elecsys Anti-SARS-CoV-2 chemiluminescence immunoassay.
    Lippi G; Salvagno GL; Pegoraro M; Militello V; Caloi C; Peretti A; De Nitto S; Bovo C; Lo Cascio G
    Clin Chem Lab Med; 2020 Oct; 58(11):e251-e253. PubMed ID: 32692698
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.